CoronaVac, BNT162b2 and heterologous COVID-19 vaccine and ventricular assist device: Correspondence

Dear Editor,

We would like to share ideas on the publication “CoronaVac, BNT162b2 and heterologous COVID-19 vaccine outcomes in patients with ventricular assist device (VAD).” ¹ In patients with VAD, Karahan et al. ¹ evaluated the clinical result of an inactivated, mRNA, and heterologous vaccine program. According to the type of vaccine used—“inactivated,” “mRNA,” and “heterologous”—the patients were split into three groups. Analysis of clinical results was done. ¹ The study found that there was no pump thrombosis in the “inactivated” group. No deaths or intubations associated with COVID-19 were reported. ¹ According to Karahan et al., ¹ all COVID-19 vaccines administered on individuals with VAD are secure and efficient. MRNA vaccines can then be produced as boosters in nations where inactivated vaccinations are prioritized.

We both believe that vaccine recipients with underlying medical conditions may respond to the vaccine differently than ones in good health. To get at the correct interpretation, a number of factors must be taken into account. A genuine bad reaction was one of the possible confounding factors that might have had an impact on the results of the initial dose. Examples include the COVID-19 strain, the delivery mechanism, the setting, and the recipient’s co-morbidity prior to vaccination. The absence of clinical symptoms and asymptomatic COVID-19 may be related. ² If neither the preceding symptoms nor the current symptoms are present, a COVID-19 must be ruled out. The chance of cross-contamination with an unidentified SARS-Co-V2 infection cannot be completely ruled out. It has also been investigated and confirmed that inherited genetic variation affects the immune responses of vaccination recipients. ³ More empirical study should be conducted to ascertain whether or not the conclusions of the current paper are supported.